Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Equity Average (2019 - 2026)

Opus Genetics has reported Equity Average over the past 12 years, most recently at -$15.2 million for Q1 2026.

  • Quarterly Equity Average fell 358.44% to -$15.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$15.2 million through Mar 2026, down 358.44% year-over-year, with the annual reading at $11.0 million for FY2025, 61.02% down from the prior year.
  • Equity Average was -$15.2 million for Q1 2026 at Opus Genetics, down from $10.7 million in the prior quarter.
  • Over five years, Equity Average peaked at $50.1 million in Q4 2023 and troughed at -$15.2 million in Q1 2026.
  • The 5-year median for Equity Average is $20.5 million (2024), against an average of $25.2 million.
  • Year-over-year, Equity Average surged 1181.73% in 2022 and then tumbled 358.44% in 2026.
  • A 5-year view of Equity Average shows it stood at $29.1 million in 2022, then surged by 72.39% to $50.1 million in 2023, then plummeted by 59.05% to $20.5 million in 2024, then tumbled by 48.04% to $10.7 million in 2025, then tumbled by 243.04% to -$15.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Equity Average are -$15.2 million (Q1 2026), $10.7 million (Q4 2025), and $11.7 million (Q3 2025).